Home REIT PLC Update on Potential Litigation

RNS Number : 0366L

Home REIT PLC

18 April 2024

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

18 April 2024

Home REIT plc

 

("Home REIT" or the "Company")

 

Update on Potential Litigation

The Company has recently issued a comprehensive response to a pre-action letter of claim received from Harcus Parker Limited, on behalf of certain shareholders. The letter of claim alleges that the Company, along with certain other parties, provided information to investors which was false, untrue and/or misleading.  

The Company intends vigorously to defend itself in respect of the threatened litigation and has denied the allegations made against it.

Further, as announced on 5 March 2024, the Company intends to bring legal proceedings against those parties it considers are responsible for wrongdoing. To that end, the Company has itself recently issued pre-action letters of claim to Alvarium Fund Managers (UK) Limited (its former alternative investment fund manager) and AlTi RE Limited, its former investment adviser's appointed representative. The Company intends to issue further pre-action correspondence in due course.

The Company cannot comment any further on these issues at this stage as to do so may prejudice the Company's position in any potential proceedings. Any relevant announcements in this regard will be made at the appropriate time.

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

  

FTI Consulting (Communications Adviser) Dido Laurimore Eve Kirmatzis Oliver Harrison

[e-mail] [phone]

 

The Company's LEI is: 213800A53AOVH3FCGG44.

 

For more information, please visit the Company's website: www.homereituk.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCSFMFMWELSEDL